贝林妥欧单抗在儿童急性淋巴细胞白血病中的当前与未来应用
儿童急性淋巴细胞白血病(ALL)经风险适配化疗后高收入国家总生存率已超90%,需免疫治疗进一步改善结局。贝林妥欧单抗为CD3/CD19双特异性抗体,已获FDA批准用于成人和儿童(≥1月龄)B-ALL多药化疗巩固期。儿童B-ALL随机研究显示,在复发/难治及一线治疗中,贝林妥欧单抗联合化疗或替代强化化疗较单纯常规化疗结局更好、不良反应更少。
要点
- 贝林妥欧单抗联合或替代化疗在儿童B-ALL中较常规化疗结局更好、不良反应更少
- 耐药与高白血病负荷、CD19丢失/下调及T细胞功能障碍相关
- 需培训给药与监测细胞因子释放综合征、神经毒性及低丙种球蛋白血症
核心结论
- 贝林妥欧单抗在儿童B-ALL复发/难治及一线治疗中,联合化疗或替代强化化疗较单纯常规化疗结局更好且不良反应更少。
- 贝林妥欧单抗对髓外病变尤其中枢神经系统疗效有限,且耐药与高ALL负荷、CD19丢失/下调及T细胞功能障碍相关。
研究设计与样本
- 综述总结儿童B-ALL中贝林妥欧单抗的随机研究证据,涵盖复发/难治与一线治疗设置。
主要发现
- 高收入国家儿童ALL总生存率现已超过90%,归因于风险适配化疗和支持治疗改善。
- 贝林妥欧单抗为CD3/CD19双特异性抗体,FDA批准用于成人和儿童(≥1月龄)B-ALL多药化疗巩固期。
- 贝林妥欧单抗血清半衰期短,需持续静脉输注,可致细胞因子释放综合征、免疫效应细胞相关神经毒性综合征及低丙种球蛋白血症。
关键数值与推荐
- FDA批准贝林妥欧单抗用于成人和儿童(≥1月龄)B-ALL多药化疗巩固期。
临床怎么用
- 医护人员需接受贝林妥欧单抗给药及不良反应监测培训。
- 皮下给药开发将使贝林妥欧单抗输注更便捷。
- 贝林妥欧单抗联合其他免疫治疗和分子靶向治疗以减少或消除常规化疗的一线可行性需进一步评估。
局限性
- 贝林妥欧单抗长期不良反应尚不明确,需纵向监测。
- 高收入国家经验需扩展至中低收入国家,后者ALL结局欠佳。
- 贝林妥欧单抗对髓外病变尤其中枢神经系统疗效有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment outcomes for pediatric acute lymphoblastic leukemia (ALL) have improved considerably, with overall survival rates in high-income countries now exceeding 90% as a result of the introduction of risk-adapted chemotherapy and improved supportive care. Further improvement in the outcome of ALL requires new approaches, such as immunotherapy. Blinatumomab, a bispecific antibody to CD3 and CD19, is approved by the U.S. Food and Drug Administration for use in the consolidation phase of multi-agent chemotherapy for B-ALL in adults and children (aged ≥1 month). Randomized studies in pediatric patients with B-ALL in the relapsed/refractory and frontline settings have shown that blinatumomab, when added to chemotherapy or used to replace intensive chemotherapy, results in better outcomes and fewer adverse effects than are observed with conventional chemotherapy alone. Resistance to blinatumomab is associated with high ALL burden, CD19 loss/downregulation, and T-cell dysfunction, and its efficacy against extramedullary disease, especially in the central nervous system, is limited. In addition, the serum half-life of blinatumomab is short, necessitating continuous intravenous infusion, and it can cause distinct adverse effects such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and hypogammaglobulinemia. Therefore, medical staff require training in administering blinatumomab and monitoring its adverse effects. The development of subcutaneous administration of blinatumomab will make its delivery easier. Whether it is feasible to reduce or eliminate conventional chemotherapy by combining blinatumomab, other forms of immunotherapy, and molecular targeting therapy to improve outcomes while reducing adverse effects requires further evaluation in the frontline setting. Furthermore, longitudinal monitoring is necessary to evaluate the as-yet-unknown long-term adverse effects. Lastly, the experience obtained with blinatumomab in high-income countries should be expanded to low-/middle-income countries, where most of the global population reside and where the outcomes of ALL are suboptimal.
引用
- Lertvivatpong N, Inaba H. Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use. Leukemia. 2026. PMID: 42045557. doi:10.1038/s41375-026-02962-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。